Open access · OA
via Europe PMC
A Cross-Disease Microglial Transcriptional Program Characterizes Neurodegeneration and Highlights SPP1 as a Biomarker.
Palma A, Stefanelli R, Trenta F, Projetti C, Massa G, Canterini S, Fiorenza MT.
Glia · 2026
Abstract
Microglial cells are key players in maintaining brain homeostasis and responding to pathological conditions. Their multifaceted roles in health and disease have garnered significant attention in the context of neurodegeneration. In recent years, single-cell transcriptomic techniques have provided unprecedented insights into microglial heterogeneity, revealing distinct subpopulations and gene expression patterns associated with neuroprotection or neurotoxicity. Here, we dissect the transcriptomic landscape of microglia by leveraging human single-nuclei RNA sequencing datasets from multiple neurodegenerative conditions, including Amyotrophic Lateral Sclerosis, frontotemporal dementia, Alzheimer's disease, aging, and Parkinson's disease. This integrative analysis identifies distinct microglial subpopulations, reflecting functional heterogeneity across diseases and reveals a shared cross-disease microglial transcriptional program associated with inflammatory and neurodegenerative processes. Using a machine learning framework, we further demonstrate that this transcriptional program enables robust discrimination between neurodegenerative and control samples. Experimental validation in primary microglia isolated from a mouse model of Niemann-Pick disease type C, also known as juvenile Alzheimer's disease, supports the conservation of key components of this program and highlights Spp1 as a biomarker of disease-associated microglia states. Overall, this study provides an improved portrait of microglia transcriptional remodeling across neurodegenerative disorders and offers a framework for identifying conserved molecular features that may inform therapeutic strategies aimed at modulating microglial activity to mitigate disease progression and foster neuroprotection.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/glia.70163
- Canonical
- link ↗
- Fetched
- 2026-07-02 MST
Cite this
APA
A, P., R, S., F, T., C, P., G, M., S, C., & MT., F. (2026). A Cross-Disease Microglial Transcriptional Program Characterizes Neurodegeneration and Highlights SPP1 as a Biomarker. <em>Glia</em>. https://doi.org/10.1002/glia.70163
Vancouver
A P, R S, F T, C P, G M, S C, et al. A Cross-Disease Microglial Transcriptional Program Characterizes Neurodegeneration and Highlights SPP1 as a Biomarker. Glia. 2026. doi:10.1002/glia.70163.
BibTeX
@article{palma2026ACross,
title = {A Cross-Disease Microglial Transcriptional Program Characterizes Neurodegeneration and Highlights SPP1 as a Biomarker.},
author = {Palma A and Stefanelli R and Trenta F and Projetti C and Massa G and Canterini S and Fiorenza MT.},
journal = {Glia},
year = {2026},
doi = {10.1002/glia.70163},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Frontiers in Aging Neuroscience 2022
Open access · CC-BY
Aged Microglia in Neurodegenerative Diseases: Microglia Lifespan and Culture Methods
Translational Neurodegeneration 2025
Open access · CC-BY
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications
Translational neurodegeneration 2025
Open access · OA
Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.
Frontiers in aging 2026
Open access · OA
The lifespan and healthspan extending effects of ellagic acid in <i>Caenorhabditis elegans</i> require an intact insulin/IGF-1 signaling pathway.
Biological Chemistry 2009
Open access · OA
Glutathione dysregulation and the etiology and progression of human diseases
bioRxiv (Cold Spring Harbor Laboratory) 2021
Preprint · OA